Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
- PMID: 29420181
- DOI: 10.1158/2159-8290.CD-RW2018-017
Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
Abstract
Nivolumab plus ipilimumab achieves higher response rates than previously reported for nivolumab alone.
©2018 American Association for Cancer Research.
Comment on
-
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. J Clin Oncol. 2018. PMID: 29355075
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical